La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (December 2017)

13 slides from La Jolla Pharmaceutical's investor presentation, Dec 29, 2017

  1. Slide 1: Corporate Presentation: GIAPREZA (angiotensin II) Update

    0 ™ Corporate Presentation GIAPREZA™ (angiotensin II) Update NASDAQ: LJPC December 2017

  2. Slide 2: Forward Looking Statement

    1 Forward Looking Statement These slides contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to expectations regarding future events or La Jolla’s future results of operations. These statements are only predictio

  3. Slide 3: GIAPREZA Now Approved

    2 GIAPREZA™ Now Approved GIAPREZA (angiotensin II) Injection for Intravenous Infusion is indicated to increase blood pressure in adults with septic or other distributive shock "We appreciate FDA's rapid review and approval of GIAPREZA and are especially grateful to the patients, families and dedicat

  4. Slide 4: Mission Statement

    3 Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life-threatening diseases by discovering and developing innovative therapies 3

  5. Slide 5: Shock: Deadly, Costly and Prevalent

    4 Shock MORTALITY RATES COMPARED Shock: Deadly, Costly and Prevalent 1. Vincent JL, De Backer D. N Engl J Med. 2013;369(18):1726-1734. 2. Sviri S, Hashoul J, Stav I, van Heerden PV. J Crit Care. 2014;29(1):157-160. 3. Readmissions and deaths-national. Data.Medicare.gov website. https://data.medicare

  6. Slide 6: Distributive Shock is the Most Common Type of Shock in the Inpatient Setting

    5 Prevalence Types of Shock Distributive Shock is the Most Common Type of Shock in the Inpatient Setting1 1. Vincent JL, De backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-34. Distributive (94% is Septic Shock) Obstructive 66% 16% 16% Cardiogenic Hypovolemic Distributive Shock Hypovolem

  7. Slide 7: Distributive Shock is Costly

    6 Distributive Shock is Costly Source: CMS FY14 Inpatient Public Use File (IPUF) $87,282 $42,243 $31,453 $30,702 Severe Distributive Shock AMI CHF Pneumonia Weighted Average CMS Covered Charges Abbreviations: AMI=acute myocardial infarction; CHF=congestive heart failure. An average day in the ICU co

  8. Slide 8: GIAPREZA Provides a New Approach For Increasing Blood Pressure In Distributive Shock

    7 GIAPREZA Provides a New Approach For Increasing Blood Pressure In Distributive Shock THERAPIES AND MECHANISMS SYMPATHETIC NERVOUS ARGININE- VASOPRESSIN RENIN ANGIOTENSIN- ALDOSTERONE 7 CATECHOLAMINES1: SYMPATHETIC NERVOUS VASOPRESSIN: ARGININE-VASOPRESSIN GIAPREZA™ (angiotensin II) Injection for I

  9. Slide 9: GIAPREZA: A Novel Vasopressor For Patients with Distributive Shock

    8 GIAPREZA: A Novel Vasopressor For Patients with Distributive Shock A Unique Mechanism of Action - First and only synthetic human angiotensin II Robust Response - 70% Patients achieved and maintained target MAP primary endpoint at hour 3 Rapid Response - Median response time to reach target MAP was

  10. Slide 10: Distributive Shock is Prevalent

    9 Distributive Shock is Prevalent 9 1. Standard of Care percentages estimated lines of therapy calculations based on Second Line estimate. Percentages based on Vincent JL, De backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-34 and Decision Resources Group market research. 2. SHA Integrat

  11. Slide 11: Preparing For Commercialization in 2018

    10 Preparing For Commercialization in 2018 Commercial • Market Research • Healthcare Professional Marketing • Multi-Channel Marketing • Professional Education • Commercial Insights & Operations • Market Access Field Sales • National and Regional Sales Leadership* • Critical Care Nurse Educators* • H

  12. Slide 12: Financial Position

    11 Financial Position Condensed Balance Sheet Data As of September 30, 2017 (in millions) Cash $120.8 Total liabilities $10.3 Total shareholders’ equity1 $119.8 Fully Diluted, As-Converted Shares Outstanding1 34,017,102 1 Includes common stock, preferred stock (as-converted), and outstanding equity

  13. Slide 13: @) La Jolla”

    he @) La Jolla”

LA Jolla Pharmaceutical — Investor Presentation (December 2017) on 6ix